Quatro anos de experiência no tratamento trombolítico do AVC Isquêmico na cidade de Porto Alegre

Autores

  • Sheila Cristina Ouriques Martins Neurologista vascular do Instituto de Medicina Vascular do Hospital Mãe de Deus (HMD) e da Unidade Vascular do Hospital de Clínicas de Porto Alegre (HCPA)
  • Rosane Brondani Neurologista vascular do Instituto de Medicina Vascular do Hospital Mãe de Deus (HMD) e da Unidade Vascular do Hospital de Clínicas de Porto Alegre (HCPA)
  • Maurício Friedrich Coordenador do programa de Doenças Neurovasculares do Hospital São Lucas da Pontifícia Universidade Católica do Rio Grande do Sul (HSL-PUCRS) e do Hospital Mãe de Deus (HMD)
  • Mariana Dagnino Araújo Neurologista Vascular do HSL-PUCRS e do Instituto de Medicina Vascular do HMD
  • Adriano Wartchow Neurologista Vascular do HSL-PUCRS e do Instituto de Medicina Vascular do HMD
  • Paulo Passos Neurorradiologista intervencionista do Instituto de Medicina Vascular do HMD
  • Euler Manenti Chefe da Unidade de Terapia Coronariana do HSL-PUCRS, responsável pela área de trombocardiologia do Instituto de Medicina Vascular do HMD
  • Cristiano Jaeger Cardiologista do Instituto de Medicina Vascular do HMD
  • Rafael Rech Cardiologista do Instituto de Medicina Vascular do HMD
  • Daniel Silveira Cardiologista do Instituto de Medicina Vascular do HMD
  • Karen Ruschel Enfermeira de pesquisa do Instituto de Medicina Vascular do HMD
  • Luiz Antonio Nasi Chefe do Serviço de Emergência e da Unidade Vascular do HCPA
  • Márcia Lorena Fagundes Chaves Chefe do Serviço de Neurologia do HCPA
  • João Arthur Ehlers Coordenador Geral do Instituto de Medicina Vascular do Hospital Mãe de Deus

DOI:

https://doi.org/10.34024/rnc.2006.v14.8784

Palavras-chave:

Acidente Cerebrovascular, Terapia trombolítica

Resumo

Embora o benefício do tratamento trombolítico no AVC isquêmico esteja bem demonstrado, o impacto na população geral de pacientes com AVC ainda é limitado, principalmente devido a estreita janela terapêutica. No Brasil, poucos centros estão estruturados para o uso do rtPA no AVC isquêmico agudo. Nós apresentamos os resultados de 4 anos de experiência em terapia trombolítica, com 173 pacientes tratados em 3 Unidades Vasculares implementadas em hospitais gerais no Sul do Brasil.

Métricas

Carregando Métricas ...

Downloads

Não há dados estatísticos.

Referências

The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group (NINDS). Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.

Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation 1996;94:1167-1174.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (NINDS). A systems approach to immediate evaluation and management of hyperacute stroke: experience at eight centers and implications for community practice and patient care. Stroke 1997;28:1530-1540.

Schwamm LH, Pancioli A, Acker III JE, Goldstein LB, Zorowitz RD, Shepard TJ, et al. Recommendations from the American Stroke Association’s Task Force on the development of stroke systems. Stroke 2005; 36: 690-703.

Grotta JC, Burgin WS, Mitwalli A, Long M, Campbell M, Morgenstern LB, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996-2000. Arch Neurol 2001;58:2009-2013.

Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzan DM. Cleveland Clinic health system stroke quality improvement team. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003;34: 799–800.

Sociedade Brasileira de Doenças Cerebrovasculares. Primeiro consenso brasileiro do tratamento da fase aguda do acidente vascular cerebral. Arq Neuropsiquiatr 2001;59:972-980.

Adams HP, Adams RJ, Brott T, del Zoppo GJ, Furlan A, Goldstein LB, et al. Stroke Council of the American Stroke Association. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the stroke council of the American Stroke Association. Stroke 2003;34:1056-83.

Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the stroke council of the American Stroke Association. Stroke 2005;36:916-921.

Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20:864-870.

Rankin J. Cerebral vascular accidents in patients over the age of 60: II. Prognosis. Scot Med J 1957; 2: 200-215.

The ATLANTIS, ECASS, and NINDS rtPA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rtPA stroke trials. Lancet 2004;363:768-774.

Hill MD, Buchan AM, for the Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172:1307-1312.

Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuthner A, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998;29:1544-1549.

Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intraarterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial. JAMA 1999;282:2003-2011.

del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: A Phase II Randomized Trial of Recombinant Pro-Urokinase by Direct Arterial Delivery in Acute Middle Cerebral Artery Stroke. Stroke 1998;29:4-11.

Lisboa RC, Jovanovic BD, Alberts MJ. Analysis of the safety and efficacy of intraarterial thrombolytic therapy in ischemic stroke. Stroke 2002;33:2866-2871.

The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (NINDS). Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA stroke trial. Stroke 1997;28:2119-2125.

Ernst R, Pancioli A, Tomsick T, Kissela B, Woo D, Kanter D, et al. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 2000;31:2552-2557.

Wolpert S, Bruckmann H, Greenlee R, Wechsler L, Pessin M, del Zoppo G. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. Am J Neuro Radiol 1993;14:3-13.

Mori E, Yoneda Y, Tabuchi M, Yochida T, Ohkawa S, Ohsumi Y, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;1992:976-982.

Downloads

Publicado

2006-03-31

Como Citar

Martins, S. C. O., Brondani, R., Friedrich, M., Araújo, M. D., Wartchow, A., Passos, P., … Ehlers, J. A. (2006). Quatro anos de experiência no tratamento trombolítico do AVC Isquêmico na cidade de Porto Alegre. Revista Neurociências, 14(1), 31–36. https://doi.org/10.34024/rnc.2006.v14.8784

Edição

Seção

Artigos Originais

Artigos Semelhantes

1 2 3 4 5 6 7 8 9 10 > >> 

Você também pode iniciar uma pesquisa avançada por similaridade para este artigo.

Artigos mais lidos pelo mesmo(s) autor(es)